Table 3 Efficacy outcomes of advanced pancreatic cancer patients by investigator assessment

From: Dynamic transcriptional immune landscape in response to NK-cell therapy combined with gemcitabine plus S-1 in advanced pancreatic cancer: a phase 1b/2 trial

Responses (RECIST v1.1)

Advanced pancreatic cancer (n = 19)

Metastatic pancreatic cancer (n = 16)

Best overall response,

 PR, No. (%)

6 (31.6)

4 (25.0)

 SD, No. (%)

8 (42.1)

7(43.8)

 PD, No. (%)

5 (26.3)

5 (31.2)

 ORR, No. (%) [95% CI]

6 (31.6) [12.6, 56.6]

4 (25.0) [7.3, 52.4]

 DCR, No. (%) [95% CI]

14 (73.7) [48.8, 90.9]

11 (68.8) [41.3, 89.0]

 mPFS(months) [95% CI]

6.6 [3.0, 12.5]

6.5 [1.5, NR]

 6-months PFS rate (%) [95% CI]

57.4 [38.8, 84.9]

49.2 [29.7, 81.6]

 mOS(months) [95% CI]

10.8 [7.3, 21.9]

10.2 [6.3, 21.9]

 6-months OS rate (%) [95% CI]

78.0 [61.1, 69.3]

75.0 [56.5, 99.5]

  1. CR complete response, DCR disease control rate, NA not applicable, ORR objective response rate, PD progressive disease, PR partial response, SD stable disease
Back to article page